Molecular monitoring in CML - getting to a safe place

Molecular monitoring in CML - getting to a safe place

Martin C. Müller, Institute for Hematology and Oncology (IHO) and Medical Faculty Mannheim, University of Heidelberg, Germany 

• What do we consider safe?
• Cytogenetic and molecular monitoring: European LeukemiaNet recommendations
• Molecular monitoring every 3 months - enough for all patients?
• Achieving deep remissions
• Definitions of molecular response
• Compliance check
• Conclusions